Whether Facebook Inc (NASDAQ:FB), SolarCity Corp (NASDAQ:SCTY) and Intercept Pharmaceuticals Inc (NASDAQ:ICPT) will join the Dow in 25 years was discussed by Dominic Chu in a segment on CNBC.
The discussion about Facebook Inc (NASDAQ:FB), SolarCity Corp (NASDAQ:SCTY) and Intercept Pharmaceuticals Inc (NASDAQ:ICPT) comes as Chu was looking into which companies will be large enough to be included in the Dow in the next 25 years.
According to the CNBC personality, in 25 years, names like Amazon.com, Inc. (NASDAQ:AMZN) may be included in the Dow in the retail side. Celgene Corporation (NASDAQ:CELG) was also named as a possible entry. Chu remarked that CNBC’s Jim Cramer loves the company and thinks it will cure more diseases in the next 10 years than any other company in the space.
He said that his team thought about younger companies when they joined. Names like Microsoft Corporation (NASDAQ:MSFT) and Cisco Systems, Inc. (NASDAQ:CSCO) cropped up and pointed to the possibility that Facebook Inc (NASDAQ:FB), SolarCity Corp (NASDAQ:SCTY) and Intercept Pharmaceuticals Inc (NASDAQ:ICPT) may also join the Dow in the next two and a half decades.
He said one of the companies they looked at is Facebook Inc (NASDAQ:FB) which now has a market cap of $174 billion.
It gets a little bit more interesting, he noted, when he looked at the energy and utilities side. He mentioned SolarCity Corp (NASDAQ:SCTY) and how it has jumped 788% since its initial public offering.
On the healthcare side, he mentioned Intercept Pharmaceuticals Inc (NASDAQ:ICPT) which has seen its share price increase at a massive 1,467% since its IPO.
Watch the discussion below.
Facebook Inc (NASDAQ:FB) investors includes Jeffrey Jon Berney’s Trioaks Capital Management which had 175,000 shares in the company by the end of the first quarter of the year. Another hedge fund with a stake in the company is Meru Capital managed by Guru Ramakrishnan which reported 160,000 shares also by the end of the first quarter.
SolarCity Corp (NASDAQ:SCTY) shareholders includes John Thaler’s Jat Capital Management which had about 2.39 million shares in the company by the end of March. Also by the end of March, Daniel Benton’s Andor Capital Management reported 1.5 million shares in the company.
Meanwhile, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has Samuel Isaly’s Orbimed Advisors as an investor. The hedge fund reported about 1.73 million shares in the company by the end of the first quarter. In the same period, Andreas Halvorsen’s Viking Global said it had 454,917 shares in the company.
Disclosure: None
